Seven Fleet Capital Management LP Makes New Investment in Eupraxia Pharmaceuticals Inc. $EPRX

Seven Fleet Capital Management LP acquired a new position in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 610,785 shares of the company’s stock, valued at approximately $4,037,289,000. Eupraxia Pharmaceuticals accounts for about 0.7% of Seven Fleet Capital Management LP’s holdings, making the stock its 29th largest holding. Seven Fleet Capital Management LP owned approximately 0.94% of Eupraxia Pharmaceuticals at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Royal Bank of Canada raised its stake in Eupraxia Pharmaceuticals by 21.1% in the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after acquiring an additional 59,683 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after purchasing an additional 16,017 shares during the period. Bank of America Corp DE increased its holdings in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares during the period. UBS Group AG raised its stake in shares of Eupraxia Pharmaceuticals by 155.4% in the third quarter. UBS Group AG now owns 95,756 shares of the company’s stock worth $565,000 after purchasing an additional 58,257 shares during the last quarter. Finally, Raymond James Financial Inc. lifted its holdings in shares of Eupraxia Pharmaceuticals by 173.3% during the third quarter. Raymond James Financial Inc. now owns 33,373 shares of the company’s stock worth $197,000 after purchasing an additional 21,161 shares during the period.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX stock opened at $7.43 on Thursday. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. Eupraxia Pharmaceuticals Inc. has a 12-month low of $5.07 and a 12-month high of $9.32. The business’s 50 day moving average is $6.58 and its two-hundred day moving average is $7.05. The company has a market capitalization of $483.10 million, a P/E ratio of -7.28 and a beta of 1.08.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. Analysts expect that Eupraxia Pharmaceuticals Inc. will post -0.87 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Stifel Nicolaus began coverage on Eupraxia Pharmaceuticals in a research report on Thursday, May 21st. They issued a “buy” rating and a $25.00 target price on the stock. Oppenheimer initiated coverage on Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They set an “outperform” rating and a $17.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Eupraxia Pharmaceuticals in a report on Monday, May 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, July 15th. Finally, Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Eupraxia Pharmaceuticals Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.